Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
20
XTLB Quote, Financials, Valuation and Earnings
Last price:
$1.49
Seasonality move
:
19.96%
Day range:
$1.43 - $1.50
52-week range:
$0.76 - $4.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.90x
Volume:
2.6K
Avg. volume:
11.1K
1-year change:
46.97%
Market cap:
$7.8M
Revenue:
--
EPS (TTM):
-$0.03
Analysts' Opinion
-
Consensus RatingXTL Biopharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, XTL Biopharmaceuticals has an estimated upside of 1983.33% from its current price of $1.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.44.
Fair Value
-
According to the consensus of 0 analysts, XTL Biopharmaceuticals has 1983.33% upside to fair value with a price target of -- per share.
XTLB vs. S&P 500
-
Over the past 5 trading days, XTL Biopharmaceuticals has underperformed the S&P 500 by -18.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
XTL Biopharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
XTL Biopharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter XTL Biopharmaceuticals reported revenues of --.
Earnings Growth
-
XTL Biopharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter XTL Biopharmaceuticals reported earnings per share of $0.10.
Enterprise value:
5.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
8.74x
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-2.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
8.74x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$1M | -$882K | -$689K | -$251K | -$175K | |
| EBITDA | -$809K | -$2.3M | $630K | -$894K | $501K | |
| Diluted EPS | $0.06 | -$0.51 | -$0.03 | -$0.17 | $0.10 | |
| Period Ending | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.9M | $6.9M | $6.2M | $2.9M | $2.5M | |
| Total Assets | $7.3M | $7.3M | $6.6M | $3.3M | $2.9M | |
| Current Liabilities | $244K | $251K | $260K | $241K | $223K | |
| Total Liabilities | $244K | $2.9M | $777K | $241K | $223K | |
| Total Equity | $7M | $4.4M | $5.8M | $3.1M | $2.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2012-12-31 | 2013-12-31 | 2014-12-31 | 2013-12-31 | 2014-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$2.5M | -$2.5M | -$520K | -$674K | |
| Cash From Investing | -$1.2M | $3.3M | $1.5M | -$945K | $516K | |
| Cash From Financing | $4.3M | $317K | $309K | $172K | -- | |
| Free Cash Flow | -$1.6M | -$2.6M | -$2.5M | -$521K | -$674K | |
XTLB
Sector
Market Cap
$7.8M
$44.6M
Price % of 52-Week High
28.86%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
46.97%
-29.09%
Beta (5-Year)
1.156
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.63
200-day SMA
Sell
Level
$2.32
Bollinger Bands (100)
Sell
Level
1.8 - 2.62
Chaikin Money Flow
Sell
Level
-37.5M
20-day SMA
Sell
Level
$1.77
Relative Strength Index (RSI14)
Sell
Level
30.63
ADX Line
Sell
Level
8.77
Williams %R
Buy
Level
-96.875
50-day SMA
Sell
Level
$1.83
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
33.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Stock Forecast FAQ
In the current month, XTLB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XTLB average analyst price target in the past 3 months is --.
-
Where Will XTL Biopharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that XTL Biopharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About XTL Biopharmaceuticals?
Analysts are divided on their view about XTL Biopharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that XTL Biopharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is XTL Biopharmaceuticals's Price Target?
The price target for XTL Biopharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XTLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for XTL Biopharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XTLB?
You can purchase shares of XTL Biopharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase XTL Biopharmaceuticals shares.
-
What Is The XTL Biopharmaceuticals Share Price Today?
XTL Biopharmaceuticals was last trading at $1.49 per share. This represents the most recent stock quote for XTL Biopharmaceuticals. Yesterday, XTL Biopharmaceuticals closed at $1.44 per share.
-
How To Buy XTL Biopharmaceuticals Stock Online?
In order to purchase XTL Biopharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
